The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
By 2030, How Much Growth In Market Size Is Expected For The Praluent Market?
Historical growth was driven by the increasing incidence of hypercholesterolemia, the inherent limitations of statin-only treatments, and a rise in cardiovascular risk screening. Additionally, the expansion of biologic cardiovascular drugs and the growing availability of specialist cardiology care also contributed significantly.
Projected expansion during the forecast period is driven by an increased emphasis on aggressive strategies for lowering lipids, broader adoption in secondary prevention efforts, the growth of value-based cardiovascular care models, rising support from payers for pcsk9 inhibitors, and a heightened awareness regarding cardiovascular risk reduction.
Major developments expected in the forecast period include the expanding application of pcsk9 inhibitors in lipid management, increasing uptake among high-risk cardiovascular patients, greater integration with statin combination therapies, the enlargement of preventive cardiology programs, and an intensified focus on long-term control of LDL levels.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20261&type=smp
Which Core Factors Are Supporting The Expansion Of The Praluent Market?
An anticipated increase in obesity is set to stimulate the expansion of the Praluent market. This condition is medically defined by an unhealthy accumulation of body fat that poses health risks, typically indicated by a Body Mass Index (BMI) of 30 or greater. The growing prevalence of obesity is attributed to shifts in global food systems and dietary habits, marked by increased consumption of ultra-processed foods, sedentary lifestyles, and economic factors that make less healthy food options more accessible. Praluent addresses obesity by functioning as a PCSK9 inhibitor, which enhances the liver’s capacity to remove LDL cholesterol from the bloodstream. This action lowers LDL cholesterol levels in individuals with obesity-related dyslipidemia, thereby improving cardiovascular health and reducing complications associated with obesity. For example, data from May 2024, released by the Office for Health Improvement and Disparities, a UK government department, indicated that an estimated 64.0% of adults (18+) in England were overweight or living with obesity during the 2022–2023 period, with 26.2% specifically living with obesity (BMI ≥ 30 kg/m²). Consequently, the increasing rates of obesity are poised to advance the Praluent market’s expansion.
What Segment Types Are Included In The Praluent Market Analysis?
The praluent market covered in this report is segmented –
1) By Indication: Primary Hypercholesterolemia, Mixed Dyslipidemia, Established Atherosclerotic Cardiovascular Disease (ASCVD)
2) By Distribution Channel: Hospitals And Clinics, Retail Pharmacies, Specialty Pharmacies
3) By End-User: Ambulatory Care, Home Care
Which Trends Are Influencing The Direction Of The Praluent Market?
Major companies within the praluent market are directing their efforts towards creating innovative solutions, including low-density lipoprotein cholesterol (LDL-C) lowering therapies, to address the growing demand for advanced treatments that reduce cardiovascular risk. LDL-C–lowering therapies are specialized medical interventions designed to significantly decrease levels of “bad cholesterol,” providing more precise, targeted, and sustained lipid control compared to traditional statins or lifestyle modifications alone. For instance, in March 2024, Regeneron Pharmaceuticals Inc., a US-based biotechnology company, obtained extended U.S. Food and Drug Administration (FDA) approval for Praluent (alirocumab) injection, an advanced LDL-C–lowering biologic therapy. This updated authorization permits its use as an add-on to diet and existing lipid-lowering treatments for pediatric patients aged 8 years and older who have heterozygous familial hypercholesterolemia (HeFH). Praluent operates as a PCSK9 inhibitor monoclonal antibody, formulated to enhance LDL receptor availability, resulting in a marked and sustained reduction in LDL-C. The therapy offers strong efficacy, a favorable safety profile, and less frequent dosing when compared to many traditional lipid-lowering options. By broadening access to children with genetic high cholesterol, the product contributes to managing early-onset cardiovascular risk and supports long-term heart health management.
Who Are The Companies Shaping The Praluent Market Landscape?
Major companies operating in the praluent market are Sanofi S.A., Regeneron Pharmaceuticals Inc.
Access The Complete Praluent Market Report:
https://www.thebusinessresearchcompany.com/report/praluent-global-market-report
Which Region Stands As The Largest Contributor To The Praluent Market?
North America was the largest region in the praluent market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the praluent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model